Gastrointestinal Cancer Educational Case Series: Management of Metastatic Adenocarcinoma of Unknown Primary Origin in a Ph+ ALL Survivor
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Secondary malignancies and chronic end-organ sequelae are significant and steadily rising consequences of cancer therapy. The workup and management of a carcinoma of unknown primary must consider the patient’s clinical presentation, radiologic and pathologic findings, and comorbidities.
We present the case of a 50-year-old female survivor of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with significant treatment-related end-organ sequelae who developed a metastatic adenocarcinoma of unknown primary 15 years following curative therapy for her ALL. The complex management issues related to the investigations and choice of therapy for this patient are reviewed.
This case discusses key issues related to the workup and management of a carcinoma of unknown primary. In addition, it illustrates the importance of taking patient comorbidities into consideration and tailoring investigations and therapy accordingly.
- Mody R, Li S, Dover DC, Sallan S, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515–23. CrossRef
- Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–43. CrossRef
- Oeffinger KC. Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr Blood Cancer. 2008;50(2 Suppl):462–7. Discussion 468. CrossRef
- Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15. CrossRef
- Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36. CrossRef
- Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27(34):5848–56. CrossRef
- Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008;26(27):4442–8. CrossRef
- Varadhachary GR, Edmonston TB, Karanth S, et al. Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP). J Clin Oncol 2010; vol 28 no. 15 (supplement, abstract 4151)
- NCCN Guidelines. Occult primary (cancer of unknown primary (CUP)) version 2.2011. http://www.nccn.org/professionals/physician_gls/PDF/occult.pdf (2010). Accessed 27 Oct 2010.
- Kwee TC, Basu S, Cheng G, et al. FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging. 2010;37:635–44. CrossRef
- Saliba T, Dorkhom S, O’Reilly EM, et al. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol. 2010;22(7):889–91. CrossRef
- Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the childhood cancer survivor study cohort. J Clin Oncol. 2009;27(14):2356–62. CrossRef
- Greco FA. Therapy of adenocarcinoma of unknown primary: are we making progress? J Natl Compr Canc Netw. 2008;6(10):1061–7.
- Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol. 2009;36(1):65–74. CrossRef
- Gastrointestinal Cancer Educational Case Series: Management of Metastatic Adenocarcinoma of Unknown Primary Origin in a Ph+ ALL Survivor
Journal of Gastrointestinal Cancer
Volume 42, Issue 3 , pp 165-170
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Carcinoma of unknown primary management
- Carcinoma of unknown primary investigations
- Secondary malignancies
- Cancer therapy-induced cardiotoxicity
- Industry Sectors
- Author Affiliations
- 1. Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- 3. Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
- 2. American University of Beirut, Beirut, Lebanon